A Phase 3 Clinical Protocol: Placebo‐Controlled, Double‐Blind, Parallel‐Group to Study the Safety and Efficacy of NA‐831 in Combination with Donanemab in Subjects with Early Alzheimer's Disease
Final results from the Phase 3 study will be announced upon completion. The findings are expected to provide valuable insights into the safety and efficacy of combination therapy with NA-831 and donanemab for early Alzheimer's disease.
Authors
- Fern Vu
- Lloyd Tran
- Zung Vu Tran (ORCID: https://orcid.org/0000-0002-9322-9562)
Institutions
- Broomfield Hospital (GB)
- Biomed Research Institute (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108266
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00